BI-1206
- Generic Name
- BI-1206
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 24S6PA0WXW
- Background
BI-1206 is a fully human immunoglobulin G1 monoclonal antibody that targets CD32b.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
Phase 1
Recruiting
- Conditions
- Indolent B-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- BioInvent International AB
- Target Recruit Count
- 140
- Registration Number
- NCT03571568
- Locations
- 🇪🇸
Hospital Universitario HM Sanchinarro, Madrid, Spain
🇪🇸Hospital University Virgen Macarene, Seville, Spain
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath